Our Recommendations
New Publications
- Interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19: interim guidance, 20 December 2021 (2022)
- Factsheet for health workers: Sinovac-CoronaVac COVID-19 vaccine, July 2021 (2021)
- ИНФОРМАЦИОННЫЙ БЮЛЛЕТЕНЬ ДЛЯ РАБОТНИКОВ ЗДРАВООХРАНЕНИЯ (2021)
- Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm (Arabic), updated March 2022 (2022)
- Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac (2022)
Filter
18
Featured
Language
Document type
Guidelines
10
Fact sheets
4
Situation Updates
2
Manuals
1
Resource Platforms
1
Countries / Regions
Russia
2
Mozambique
1
Argentina
1
Brazil
1
Authors & Publishers
Publication Years
Category
COVID-19
4
Guidelines
3
Studies & Reports
1
Toolboxes
Inactivated COVID-19 Vaccines
18
For Health Worker
2
Country specific documents
2
mRna Vaccines general
1
Vector-based Vacines General
1
Research & Pipeline
1
Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat...
orientaciones provisionales, primera publicación: 24 de mayo de 2021, actualización: 21 de octubre de 2021, actualización: 15 de marzo de 2022
Вакцина против COVID-19 CoronaVac производства компании Sinovac (Sinovac-CoronaVac) July 2021
This quick guide offers basic information about COVID-19, the Sinovac-CoronaVac COVID-19 vaccine and what to
expect following vaccination: ...
Временное руководство (Первый выпуск 24 мая 2021 г., Обновлено 21 октября 2021 г., Обновлено 15 марта 2022 г.
24 September 2021. The vaccine has been authorized by the Chinese National Regulatory Authority (NRA) – the National Medicinal Product Administration (NMPA) – as well as other regulatory authorities. Because WHO has granted Emergency Use Listing (EUL) for the COVID-19 Vaccine BIBP/ Sinopharm, th...
24 September 2021. The vaccine has been authorized by the Chinese National Regulatory Authority (NRA) – the National Medicinal Product Administration (NMPA) – as well as other regulatory authorities. Because WHO has granted Emergency Use Listing (EUL) for the Sinovac COVID-19 vaccine (Vero Cell ...
This chronology of facts has challenged public health systems worldwide and regulatory bodies are no exception. Regulatory authorities with mechanisms in place to authorize the use of investigational products had to development guidelines and procedures, create task forces and alliances to maximize ...
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Th...
27 September 2022
These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
9 Febr. 2022
The COVID Covovax™ (SIIPL) and Nuvaxovid™ (Novavax) vaccine explainer includes key vaccine specific information on the vaccine specific requirements.
Vaccinator's Manual SINOPHARM Vaccine - 28 FEBRUARY 2021
O SAGE aplica os princípios da medicina baseada em evidências e estabeleceu um processo metodológico completo para emitir ou atualizar recomendações. Especificamente para vacinas contra a COVID-19, uma descrição detalhada dos processos metodológicos pode ser encontrada no esquema de evidênc...
